How to Prepare Performance Verification Documentation for Overseas Registration of Sterile Consumables

Key Summary

The core of preparing performance verification documentation for overseas registration of sterile consumables is to first determine whether the target country regulates the product as a medical device, and then to decide the registration pathway and applicant entity based on the risk classification. Manufacturers should review existing technical documentation under NMPA, CE, FDA, ISO 13485, or MDSAP systems to identify which performance verification data can be reused directly and which must be supplemented or converted according to target market requirements.

Common risks include failing to distinguish sterilization methods and sterility assurance levels, not providing shelf life or transport verification data, not localizing labels and instructions for use, not appointing a local agent or authorized representative, and ignoring post-market surveillance and change reporting requirements. In multi-country registration scenarios involving GHWP member states, Southeast Asia, the Middle East, and Latin America, a core technical documentation library should be established, based on risk management, performance verification, biocompatibility, and stability data. A country-specific gap analysis should then be performed, followed by alignment with local language, regulatory format, and agent responsibilities to reduce redundant work and the risk of deficiencies.

When preparing documentation, manufacturers must also consider facility sterilization validation, process qualification, sampling plans, and test methods, and link the quality management system with the registration evidence chain to avoid certificate invalidation due to inadequate change control after registration.

Applicable Scenarios and Core Issues

For overseas registration of sterile consumables, performance verification documentation is not a simple collection of test reports but an evidence chain demonstrating that the product remains sterile, safe, and effective throughout its lifecycle in the target market. A common issue is that companies directly apply domestic registration data or partial CE or FDA reports to other countries, ignoring local regulatory requirements for sterile barrier systems, sterilization processes, shelf life, transport simulation, and clinical evaluation.

“Sterile consumables” typically include sterile syringes, sterile dressings, sterile surgical packs, sterile catheters, and sterile puncture kits. Different countries classify products and assign risk levels differently, which directly affects the scope and depth of performance verification. For example, the same product may be classified as Class A or Class B in a GHWP member state, or classified at a higher risk due to contact time and contact site.

The core question is not “what tests need to be done” but “what standards does the target country use to judge product safety and effectiveness.” Manufacturers must first clarify intended use, contact nature, sterilization method, and whether the product contains drugs or coatings, and then break down physical, chemical, microbiological, biocompatibility, and stability verification requirements item by item.

If a company plans to file in multiple countries simultaneously, it should not customize a full set of documents according to one country's requirements. Instead, it should build a master technical file and perform a gap analysis against each regulatory authority, which significantly reduces redundant work and the risk of deficiencies.

Registration Decision Logic

Step 1: Determine whether the product falls under the medical device regulatory scope of the target country. Most countries regulate consumables that have medical purposes and come into direct contact with the human body as medical devices or drug-device combination products. However, exceptions exist; for example, some simple packaging materials or non-medical consumables may be outside the regulatory scope.

Step 2: Determine the risk classification and registration pathway. Taking GHWP member states as an example, some countries use a classification method similar to the global harmonization working group, combining dimensions such as non-invasive, invasive, short-term, long-term, and central nervous system contact. The higher the risk class, the stricter the performance verification requirements, and clinical evaluation or clinical trials may be required.

Step 3: Evaluate the reusability of existing documentation. Companies with existing NMPA registration certificates, CE technical files, FDA 510(k) or PMA submissions should extract performance verification reports, sterilization validation reports, biocompatibility reports, and stability reports, and assess whether they meet the target market's standard versions and international standards.

Step 4: Identify the local agent or authorized representative. Most countries require overseas manufacturers to appoint a local agent responsible for registration applications, communication with regulatory authorities, receipt of adverse event reports, and post-market surveillance obligations. Contract scope, data protection, certificate control rights, and change application processes must be clarified before registration.

Step 5: Confirm local requirements for technical documentation, risk management, clinical evidence, labeling, instructions for use, and post-market maintenance. Even if performance tests are completed according to international standards, labels, instructions, symbols, language, warnings, and units must comply with local regulations; otherwise, the registration application may be rejected.

Documentation and Evidence

The core of performance verification documentation for overseas registration of sterile consumables is to demonstrate that the product maintains its intended performance after sterilization, during the storage shelf life, and during use. Specifically, this includes:

• Product description, intended use, material composition, and structural drawings.
• Sterilization validation and process qualification records.
• Sterility assurance level and sterility test methods.
• Physical performance verification, such as dimensions, leakage, tensile strength, and connection security.
• Chemical performance verification, such as extractables, heavy metals, and pH.
• Biocompatibility evaluation, typically per ISO 10993 series standards.
• Package integrity verification and shelf life verification.
• Transport simulation testing.
• Microbial barrier performance testing, including bacterial filtration efficiency for breathable packaging.

For sterile consumables containing drugs or coatings, additional data on drug content, release profile, interaction, and stability must be provided. Such products are often regulated as drugs or combination products in many countries, and the registration pathway is fundamentally different.

If a company already has an ISO 13485 quality management system, the verification reports should be linked with system records to ensure that every data point can be traced to equipment, methods, batch numbers, and acceptance criteria. During onsite inspections or deficiency responses, regulatory authorities often question the integrity of verification data from a system perspective.

Risk management reports must be prepared in parallel with performance verification documentation. ISO 14971 requires manufacturers to identify risks related to sterility, particulate contamination, package damage, and material toxicity, and to verify the effectiveness of mitigation measures. Reviewers will check whether performance verification items correspond to the risk analysis.

Clinical evaluation or clinical evidence is not required for all sterile consumables. For low-risk products with non-chronic contact and extensive clinical history, literature, clinical use history, or equivalence arguments may suffice. However, for high-risk products, new materials, new mechanisms of action, or drug-containing products, a clinical trial protocol and ethics approval are required.

Common Mistakes

• Directly translating NMPA registration test reports and submitting them without checking the target country's standard versions and test method differences.
• Ignoring the impact of sterilization methods on material performance, such as ethylene oxide residuals or radiation-induced material aging, and failing to provide corresponding verification data.
• Conducting only real-time aging for shelf life verification without accelerated aging, or using unvalidated accelerated aging conditions, resulting in unaccepted shelf life claims.
• Performing only static package integrity testing without transport vibration, pressure, temperature, and humidity simulation tests.
• Providing insufficient biocompatibility evidence by only submitting a cytotoxicity report without material chemical characterization and toxicological risk assessment.
• Failing to appoint a local agent, or the agent authorization document does not meet local notarization and translation requirements, leading to rejection of the registration application.
• Not localizing labels and instructions for use, missing local language, unit symbols, or warning statements; EN ISO 15223-1 symbols may not be applicable in all countries.
• Failing to establish a post-market surveillance plan, lacking procedures for adverse event reporting, customer complaints, and product recall.

Manufacturer Preparation Checklist

• Identify the target country and product classification, and search local regulations and guidance documents.
• Establish a product master record including material list, supplier information, production process, and critical process parameters.
• Organize existing NMPA/CE/FDA registration certificates and performance verification reports, and create a data reuse comparison table.
• Confirm the sterilization method and prepare sterilization validation reports, including microbial challenge, dose setting, and residue testing.
• Perform biocompatibility evaluation per ISO 10993 series, accompanied by chemical characterization and toxicological assessment.
• Conduct stability studies, including real-time aging, accelerated aging, package integrity, and transport simulation.
• Compile technical documentation, including risk management report, performance verification protocols and reports, and labels and instructions for use.
• Confirm the local agent's qualifications and authorization scope, and prepare required power of attorney and agreements for the local regulatory authority.
• Before submission, conduct a simulated deficiency review, having an independent regulatory person or consultant check each item against local regulations.

AIMEILI Regulatory Interpretation and Business Impact

In overseas registration of sterile consumables, the most common misjudgment is to think that “performance verification is just test reports.” In reality, regulatory authorities place more emphasis on the logical consistency between verification data and product structure, sterilization method, intended use, and risk management. At the early stage of a project, manufacturers should conduct target market regulatory research and gap analysis instead of rushing to arrange tests. This approach saves significant time and cost.

Reusable documentation includes basic material characterization, general tests that comply with international standards (such as ISO 10993 biocompatibility), ISO 11607 package validation, and ISO 11135 or ISO 11137 sterilization validation. What must be localized are labels and instructions for use, local language requirements, measurement units, regulatory information, agent agreements, and post-market surveillance systems.

Local agent and certificate control rights are critical. If a company allows the agent to hold the registration certificate, a change of agent or contract termination may lead to certificate invalidation. The contract should clearly specify certificate ownership, change application responsibilities, renewal obligations, and document handover terms to avoid post-market regulatory risks.

The most effective approach for multi-country registration is to build a master technical file and create a country-difference comparison table. Each country's local requirements are then added based on the differences, rather than reorganizing a full set of documents for each country. This reduces redundant work and minimizes deficiencies and queries arising from inconsistent data.

Manufacturers are advised to incorporate regulatory requirements into the early R&D phase, planning performance verification in sync with design input, risk management, and process validation to avoid delays caused by late-stage additional testing.

Frequently Asked Questions

Q: Can existing domestic sterility test reports be used directly for overseas registration?

A: No. Unless the report follows internationally accepted methods (e.g., ISO 11737-1) and the laboratory qualification is recognized by the target country, most countries require a sterility test report based on the local pharmacopoeia or international standards, with clear statement of sample quantity, test method, acceptance criteria, and the relationship to sterilization batches.

Q: How long does shelf life verification take?

A: If real-time aging is used, it must cover the entire shelf life, typically 12 months or longer. If accelerated aging is used, the acceleration factor must be designed according to standards such as ASTM F1980, with simultaneous real-time aging as a control. Accelerated aging data can be used for registration submission, but the real-time aging study must be continued post-market.

Q: Does the absence of an ISO 13485 certificate affect registration?

A: Most countries require manufacturers to establish a quality management system, and an ISO 13485 certificate is usually a prerequisite for registration. Even in countries that do not mandate certification, system documentation may be required as part of the technical file. Without system certification, the credibility of performance verification data will be challenged.

Continue reading: The previous article is “What Should Be Prepared Before Renewal of Overseas Registration for Sterile Consumables?” and the next article is “Can Test Reports from Active Medical Device Overseas Registration Be Reused?”